Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inion's BioRestore glass fibre bone graft substitute:

This article was originally published in Clinica

Executive Summary

Finnish firm Inion has received 510(k) clearance from the US FDA for its BioRestore bone graft substitute. The product, made from bioactive glass fibres, is designed to fill bony voids resulting from surgery or traumatic injury. The implant accelerates the formation of new bone, while gradually degrading over six months to allow the bone to fill the void. BioRestore is now approved for use in dental and cranio-maxillofacial applications, but is also being reviewed by the FDA for use in orthopaedic trauma indications. The US market for synthetic bone graft substitutes is estimated at around $158m, claimed the Tampere firm. Inion hopes to gain CE-marking for BioRestore during the second half of 2007 and plans to launch the product in Europe soon after.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049653

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel